Literature DB >> 32813034

Cardiac serum marker alterations after intraoperative radiotherapy with low-energy x-rays in early breast cancer as an indicator of possible cardiac toxicity.

Stefan Stefanovic1, Sebastian Berlit2, Elena Sperk3, Frederik Wenz3, Christel Weiß4, Frederik Trinkmann5, Marc Sütterlin2, Benjamin Tuschy2.   

Abstract

PURPOSE: To assess acute cardiac toxicity caused by intraoperative radiotherapy (IORT) with low-energy x‑rays for early breast cancer.
METHODS: We prospectively analyzed pre- and postoperative troponin I and NT-proBNP in 94 women who underwent breast-conserving surgery between 2013 and 2017 at the Department of Gynecology and Obstetrics of the University Medical Center Mannheim, Germany. Thirty-nine women received IORT using low-energy x‑rays during breast-conserving surgery while 55 patients without IORT formed the control group. Demographic and surgical parameters as well as cardiac markers were evaluated.
RESULTS: There were no significant differences concerning age and side of breast cancer between the groups. Furthermore, no significant difference between the troponin I assays of the IORT and control groups could be found (preoperatively: 0.017 ± 0.006 ng/ml vs. 0.018 ± 0.008 ng/ml; p = 0.5105; postoperatively: 0.019 ± 0.012 ng/ml vs. 0.018 ± 0.010 ng/ml; p = 0.6225). N‑terminal fragment of B‑type natriuretic peptide (NT-proBNP) was significantly higher in the control group 24 h after surgery (preoperatively: 158.154 ± 169.427 pg/ml vs. 162.109 ± 147.343 pg/ml; p = 0.56; postoperatively: 168.846 ± 160.227 pg/ml vs. 232.527 ± 188.957 pg/ml; p = 0.0279).
CONCLUSION: Troponin I levels as a marker of acute cardiac toxicity did not show any significant differences in patients who received IORT during breast-conserving surgery compared to those who did not.

Entities:  

Keywords:  Breast-conserving surgery; Cardiotoxicity; Early onset Cardiac damage; Heart enzymes; Intrabeam; Tumor bed boost

Year:  2020        PMID: 32813034      PMCID: PMC7801302          DOI: 10.1007/s00066-020-01671-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  35 in total

1.  Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results.

Authors:  P H Hardenbergh; M T Munley; G C Bentel; R Kedem; S Borges-Neto; D Hollis; L R Prosnitz; L B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

Review 2.  Troponin assays for the diagnosis of myocardial infarction and acute coronary syndrome: where do we stand?

Authors:  Arie Eisenman
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-07

3.  Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.

Authors:  Jayant S Vaidya; David J Joseph; Jeffrey S Tobias; Max Bulsara; Frederik Wenz; Christobel Saunders; Michael Alvarado; Henrik L Flyger; Samuele Massarut; Wolfgang Eiermann; Mohammed Keshtgar; John Dewar; Uta Kraus-Tiefenbacher; Marc Sütterlin; Laura Esserman; Helle M R Holtveg; Mario Roncadin; Steffi Pigorsch; Marinos Metaxas; Mary Falzon; April Matthews; Tammy Corica; Norman R Williams; Michael Baum
Journal:  Lancet       Date:  2010-07-10       Impact factor: 79.321

Review 4.  BNP as a biomarker in heart disease.

Authors:  Olli Vuolteenaho; Minna Ala-Kopsala; Heikki Ruskoaho
Journal:  Adv Clin Chem       Date:  2005       Impact factor: 5.394

5.  N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer.

Authors:  Maria P D'Errico; Luca Grimaldi; Maria F Petruzzelli; Emilio A L Gianicolo; Francesco Tramacere; Antonio Monetti; Roberto Placella; Giorgio Pili; Maria Grazia Andreassi; Rosa Sicari; Eugenio Picano; Maurizio Portaluri
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-02       Impact factor: 7.038

Review 6.  Heart-sparing radiotherapy techniques in breast cancer patients: a recommendation of the breast cancer expert panel of the German society of radiation oncology (DEGRO).

Authors:  Marciana-Nona Duma; René Baumann; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; David Krug; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2019-07-18       Impact factor: 3.621

7.  Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy (IORT) with low-energy x-rays?

Authors:  Muhammad Hammad Aziz; Frank Schneider; Sven Clausen; Elena Blank; Carsten Herskind; Muhammad Afzal; Frederik Wenz
Journal:  Radiat Oncol       Date:  2011-12-16       Impact factor: 3.481

8.  TARGIT-E(lderly)--prospective phase II study of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer.

Authors:  Christian Neumaier; Sperk Elena; Welzel Grit; Abo-Madyan Yasser; Kraus-Tiefenbacher Uta; Keller Anke; Gerhardt Axel; Sütterlin Marc; Wenz Frederik
Journal:  BMC Cancer       Date:  2012-05-08       Impact factor: 4.430

9.  Clinical aspects of intraoperative radiotherapy in early breast cancer: short-term complications after IORT in women treated with low energy x-rays.

Authors:  Benjamin Tuschy; Sebastian Berlit; Simone Romero; Elena Sperk; Frederik Wenz; Sven Kehl; Marc Sütterlin
Journal:  Radiat Oncol       Date:  2013-04-22       Impact factor: 3.481

10.  Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.

Authors:  Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.